• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫检查点抑制剂治疗背景下的严重腹泻

Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors.

作者信息

Kuo Jean R, Davis Amy D, Rodriguez Eduardo A, Vela Marcelo F, Heigh Russell I, Salomao Marcela A, Gurudu Suryakanth R

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

Department of General Internal Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

出版信息

Case Rep Gastroenterol. 2018 Nov 28;12(3):704-708. doi: 10.1159/000493183. eCollection 2018 Sep-Dec.

DOI:10.1159/000493183
PMID:30631256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6323374/
Abstract

Immune checkpoint inhibitors (ICPIs) are novel therapeutic agents targeting a variety of cancers by enhanced T cell activation. Immune-related adverse events (irAEs) commonly occur with ICPI use and can affect multiple organ systems including the gastrointestinal tract. Due to irAEs, the use of ICPIs is limited in autoimmune diseases. We present a case of microscopic colitis diagnosed after the initiation of nivolumab and a case of ipilimumab colitis and in the setting of Crohn's colitis.

摘要

免疫检查点抑制剂（ICPIs）是一类通过增强T细胞活化来靶向多种癌症的新型治疗药物。使用ICPIs时常见免疫相关不良事件（irAEs），可影响包括胃肠道在内的多个器官系统。由于irAEs，ICPIs在自身免疫性疾病中的应用受到限制。我们报告了1例在使用纳武单抗后诊断出的显微镜下结肠炎病例以及1例在克罗恩结肠炎背景下出现的伊匹单抗结肠炎病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f4b/6323374/54c798d1e0d0/crg-0012-0704-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f4b/6323374/54c798d1e0d0/crg-0012-0704-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f4b/6323374/54c798d1e0d0/crg-0012-0704-g01.jpg

相似文献

1
Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗背景下的严重腹泻
Case Rep Gastroenterol. 2018 Nov 28;12(3):704-708. doi: 10.1159/000493183. eCollection 2018 Sep-Dec.
2
Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.免疫检查点抑制剂相关性结肠炎治疗中使用英夫利昔单抗导致的急性肝损伤。
J Immunother Cancer. 2019 Feb 18;7(1):47. doi: 10.1186/s40425-019-0532-1.
3
Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review.免疫治疗下转移性黑色素瘤患者的肉芽肿性结肠炎：病例报告及文献复习。
BMC Gastroenterol. 2021 May 19;21(1):227. doi: 10.1186/s12876-021-01812-7.
4
Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis.免疫检查点抑制剂相关结肠炎和肝炎。
Clin Transl Gastroenterol. 2018 Sep 19;9(9):180. doi: 10.1038/s41424-018-0049-9.
5
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.纳武单抗联合伊匹单抗或单独使用纳武单抗治疗晚期黑色素瘤相关的神经系统严重不良事件，包括一组脑炎病例
Oncologist. 2017 Jun;22(6):709-718. doi: 10.1634/theoncologist.2016-0487. Epub 2017 May 11.
6
Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings.免疫检查点抑制剂诱发的腹泻/结肠炎：内镜及病理表现
World J Gastrointest Pathophysiol. 2019 Sep 10;10(2):17-28. doi: 10.4291/wjgp.v10.i2.17.
7
Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.伊匹木单抗、纳武单抗和帕博利珠单抗单药及联合治疗晚期黑色素瘤相关的潜在免疫相关不良事件：系统评价和荟萃分析
Front Oncol. 2020 Feb 11;10:91. doi: 10.3389/fonc.2020.00091. eCollection 2020.
8
An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.免疫检查点抑制剂相关胃肠道免疫相关不良事件九例患者的调查。
Digestion. 2020;101(1):60-65. doi: 10.1159/000504647. Epub 2019 Dec 4.
9
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.抗程序性死亡-1药物治疗后不良事件的管理
Oncologist. 2016 Oct;21(10):1230-1240. doi: 10.1634/theoncologist.2016-0055. Epub 2016 Jul 8.
10
Management of toxicities of immune checkpoint inhibitors.免疫检查点抑制剂毒性的管理。
Cancer Treat Rev. 2016 Mar;44:51-60. doi: 10.1016/j.ctrv.2016.02.001. Epub 2016 Feb 6.

引用本文的文献

1
Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC.免疫检查点抑制剂针对 PD-1/PD-L1 轴在 NSCLC 临床治疗中的治疗和全身不良事件。
Cell Transplant. 2021 Jan-Dec;30:9636897211041587. doi: 10.1177/09636897211041587.
2
Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study.英夫利昔单抗治疗类固醇抵抗性免疫相关不良事件的疗效与安全性：一项回顾性研究。
Mol Clin Oncol. 2021 Apr;14(4):65. doi: 10.3892/mco.2021.2227. Epub 2021 Feb 8.
3
Combination Compositions Composed of l-Glutamine and Si-Jun-Zi-Tang Might Be a Preferable Choice for 5-Fluorouracil-Induced Intestinal Mucositis: An Exploration in a Mouse Model.

本文引用的文献

1
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.通过白细胞介素-17阻断逆转自身免疫毒性和肿瘤反应丧失
N Engl J Med. 2017 May 18;376(20):1989-91. doi: 10.1056/NEJMc1703047.
2
Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies.抗程序性死亡蛋白1（PD-1）抗体免疫治疗所致结肠炎的组织病理学特征
Am J Surg Pathol. 2017 May;41(5):643-654. doi: 10.1097/PAS.0000000000000829.
3
PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'.
由L-谷氨酰胺和四君子汤组成的联合组合物可能是5-氟尿嘧啶诱导的肠道粘膜炎的更佳选择：在小鼠模型中的探索
Front Pharmacol. 2020 Jun 17;11:918. doi: 10.3389/fphar.2020.00918. eCollection 2020.
4
Immune-related adverse events of checkpoint inhibitors.检查点抑制剂的免疫相关不良反应。
Nat Rev Dis Primers. 2020 May 7;6(1):38. doi: 10.1038/s41572-020-0160-6.
5
Effects of Drugs and Excipients on Hydration Status.药物和辅料对水合状态的影响。
Nutrients. 2019 Mar 20;11(3):669. doi: 10.3390/nu11030669.
程序性死亡受体 1（PD-1）抑制剂相关性胃肠结肠炎：病例系列及“免疫调节性胃肠结肠炎”评估
Histopathology. 2017 Mar;70(4):558-567. doi: 10.1111/his.13118. Epub 2016 Dec 20.
4
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report.在一名晚期黑色素瘤和克罗恩病患者中使用白细胞介素-6阻断剂选择性抑制自身免疫性疾病恶化，同时保留抗肿瘤临床获益：一例病例报告
J Hematol Oncol. 2016 Sep 5;9(1):81. doi: 10.1186/s13045-016-0309-7.
5
Checkpoint inhibitors and gastrointestinal immune-related adverse events.检查点抑制剂与胃肠道免疫相关不良事件。
Curr Opin Oncol. 2016 Jul;28(4):264-8. doi: 10.1097/CCO.0000000000000292.
6
Anti-PD1-induced collagenous colitis in a melanoma patient.一名黑色素瘤患者出现抗程序性死亡蛋白1（Anti-PD1）诱导的胶原性结肠炎。
Melanoma Res. 2016 Jun;26(3):308-11. doi: 10.1097/CMR.0000000000000252.
7
Management of toxicities of immune checkpoint inhibitors.免疫检查点抑制剂毒性的管理。
Cancer Treat Rev. 2016 Mar;44:51-60. doi: 10.1016/j.ctrv.2016.02.001. Epub 2016 Feb 6.
8
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.使用抗CTLA-4单克隆抗体进行癌症免疫治疗可诱发炎症性肠病。
J Crohns Colitis. 2016 Apr;10(4):395-401. doi: 10.1093/ecco-jcc/jjv227. Epub 2016 Jan 18.
9
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.免疫检查点抑制剂在临床实践中的应用：免疫相关毒性管理的最新进展。
Transl Lung Cancer Res. 2015 Oct;4(5):560-75. doi: 10.3978/j.issn.2218-6751.2015.06.06.
10
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.与抗CTLA-4抗体相关的免疫相关不良事件：系统评价与荟萃分析。
BMC Med. 2015 Sep 4;13:211. doi: 10.1186/s12916-015-0455-8.